Publications by authors named "Steven Schwid"

Claim this Profile
A
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis.
Jeremy Hobart, Stefan Cano, Rachel Baron, Alan Thompson, Steven Schwid

Mult Scler· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease.
Steven R Schwid, Janice Bausch, David Oakes, Lynn Schuchter, Caroline Tanner

Mov Disord· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Broadening the spectrum of controls for skin biopsy in painful neuropathies.
David N Herrmann, Alec B O'Connor, Steven R Schwid, Yuwei Da, Andrew D Goodman

Muscle Nerve· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of memantine as treatment for spasticity in multiple sclerosis.
Lahar R Mehta, Michael P McDermott, Andrew D Goodman, Steven R Schwid

Mult Scler· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urate as a predictor of the rate of clinical decline in Parkinson disease.
Alberto Ascherio, Peter A LeWitt, Kui Xu, Shirley Eberly, Arthur Watts, Steven R Schwid

Arch Neurol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
Connie Marras, Anthony E Lang, Shirley W Eberly, David Oakes, Stanley Fahn, Steven R Schwid

Mov Disord· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of mobility device delivery within Department of Veterans Affairs for individuals with multiple sclerosis versus spinal cord injury.
Fabrisia Ambrosio, Michael L Boninger, Shirley G Fitzgerald, Sandra L Hubbard, Steven R Schwid

J Rehabil Res Dev· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis.
Lahar R Mehta, Robert H Dworkin, Steven R Schwid

Nat Clin Pract Neurol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D Goodman, Theodore R Brown, Lauren B Krupp, Randall T Schapiro, Steven R Schwid

Lancet· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Daniel D Mikol, Frederik Barkhof, Peter Chang, Patricia K Coyle, Douglas R Jeffery, Steven R Schwid

Lancet Neurol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
William B White, Phyllis Salzman, Steven R Schwid,

Hypertension· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain associated with multiple sclerosis: systematic review and proposed classification.
Alec B O'Connor, Steven R Schwid, David N Herrmann, John D Markman, Robert H Dworkin

Pain· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
Michael A Schwarzschild, Steven R Schwid, Kenneth Marek, Arthur Watts, Anthony E Lang

Arch Neurol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.
Lahar R Mehta, Melissa K Samuelsson, Anatole K Kleiner, Andrew D Goodman, Jennifer H Anolik, Steven R Schwid

Mult Scler· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Steven R Schwid, Hillel S Panitch

Clin Ther· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Steven R Schwid, Andrew D Goodman, Amy Weinstein, Michael P McDermott, Kenneth P Johnson

J Neurol Sci· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
J Antonelle deMarcaida, Steven R Schwid, William B White, Karen Blindauer, Stanley Fahn

Mov Disord· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rasagiline improves quality of life in patients with early Parkinson's disease.
Kevin M Biglan, Steven Schwid, Shirley Eberly, Karen Blindauer, Stanley Fahn

Mov Disord· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Futility studies: spending a little to save a lot.
Steven R Schwid, Gary R Cutter

Neurology· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.
Karen Blindauer, Ira Shoulson, David Oakes, Karl Kieburtz, Steven Schwid

Arch Neurol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a.
Steven R Schwid, Michael D Decker, Maria Lopez-Bresnahan,

Neurology· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Steven R Schwid, John Thorpe, Mohammad Sharief, Magnhild Sandberg-Wollheim, Kottil Rammohan

Arch Neurol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating fatigue in patients with MS: one step forward, one step back.
Steven R Schwid, T Jock Murray

Neurology· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MS Co-Operative REsearch (MS-CORE) group: an alternate approach to fostering multicenter studies.
Jeff Cohen, Gary Cutter, Fred Lublin, Steven Schwid

Mult Scler· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive fatigue during a test requiring sustained attention: a pilot study.
Steven R Schwid, Carolyn M Tyler, Eileen A Scheid, Amy Weinstein, Andrew D Goodman

Mult Scler· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis